Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

654
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
654
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

418
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
418
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

391
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
391
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

429
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
429
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

455
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
455
Regulation of Food Intake01:30

Regulation of Food Intake

1.9K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ginkgo biloba extract mitigates behavioral deficits, oxidative stress, and hippocampal remodeling in a rat model of PTSD.

Behavioral and brain functions : BBF·2026
Same author

Linagliptin attenuates the adverse effects of a high-sugar diet on insulin sensitivity, hippocampal oxidative stress, and cognitive function in rats.

Behavioural brain research·2026
Same author

Addition of sitagliptin to ongoing metformin improved metabolic profile and pancreatic function via normalizing inflammatory cytokines' levels in patients with type 2 diabetes, a randomized double-blinded clinical trial.

Expert review of endocrinology & metabolism·2025
Same author

The effect of combination therapy on Bevacizumab, Carmustine, and Metformin chemotherapy drugs on the fluctuating performance expression of TLR2, TLR6, and IL-6 genes in the cell line of brain glioblastoma.

Cancer cell international·2025
Same author

RETRACTED: Haghmorad et al. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses. <i>Curr. Issues Mol. Biol.</i> 2022, <i>44</i>, 5728-5740.

Current issues in molecular biology·2025
Same author

Bromelain-digested casein peptide pool mitigates stress-induced neural and behavioral deficits in rats.

International journal of biological macromolecules·2025

Related Experiment Video

Updated: Dec 3, 2025

Barnes Maze Testing Strategies with Small and Large Rodent Models
12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 26, 2014

43.1K

GLP-1 mimetics and cognition.

Habib Yaribeygi1, Ali Rashidy-Pour1, Stephen L Atkin2

  • 1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.

Life Sciences
|October 30, 2020
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 (GLP-1) receptor agonists, used for diabetes, show potential neuroprotective effects. These drugs may improve cognitive function by targeting at least eight molecular mechanisms relevant to brain health.

Keywords:
Alzheimer's diseaseCognitionDiabetes mellitusGlucagon-like peptide-1IncretinsMemory

More Related Videos

Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation
07:29

Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation

Published on: December 29, 2023

922
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.9K

Related Experiment Videos

Last Updated: Dec 3, 2025

Barnes Maze Testing Strategies with Small and Large Rodent Models
12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 26, 2014

43.1K
Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation
07:29

Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation

Published on: December 29, 2023

922
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.9K

Area of Science:

  • Neuroscience
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic patients exhibit higher incidence of cognitive dysfunction, including Alzheimer's disease.
  • Glucagon-like peptide-1 (GLP-1) receptor agonists are established antidiabetic medications.
  • Emerging evidence suggests GLP-1 receptor agonists possess properties beneficial for neurological health.

Purpose of the Study:

  • To review the pharmacologic effects of GLP-1 analogues.
  • To investigate the potential of GLP-1 analogues in mitigating cognitive disorders.
  • To identify molecular mechanisms underlying the neuroprotective effects of GLP-1 analogues.

Main Methods:

  • Literature review of pharmacologic effects of GLP-1 analogues.
  • Analysis of studies investigating GLP-1 analogues and cognitive function.
  • Identification of molecular pathways modulated by GLP-1 analogues relevant to neuroprotection.

Main Results:

  • GLP-1 receptor agonists modulate several molecular pathways involved in cognitive function.
  • At least eight distinct molecular mechanisms may contribute to the cognitive benefits of GLP-1 analogues.
  • These mechanisms suggest a potential role for GLP-1 analogues beyond glycemic control.

Conclusions:

  • GLP-1 receptor agonists demonstrate promising neuroprotective effects.
  • These agents may offer a dual benefit for diabetic patients by improving glycemic control and cognitive function.
  • Further research is warranted to explore the therapeutic potential of GLP-1 analogues in cognitive disorders.